SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna shares are surging after positive Phase 3 results for its personalized mRNA cancer vaccine, marking a major clinical milestone that has fueled intense retail excitement and a massive short squeeze. The community is actively debating the long-term potential of this new platform against traditional biotech valuations, with many traders discussing aggressive scalping strategies and the potential for a broader sector rally.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Marvell Technology is experiencing significant volatility driven by a major multi-year partnership with Google to develop custom silicon for its TPU ecosystem, which includes a substantial warrant agreement. While some investors view the deal as a landmark endorsement of Marvell's custom chip capabilities, the community is debating potential future dilution and the impact of broader market macro pressures on semiconductor sector valuations.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is currently trading in a tight range above support, with market participants closely monitoring upcoming regulatory clarity from the U.S. government. The community is actively debating whether this stability indicates a bottoming phase or a consolidation period before a broader rotation from tech equities into crypto assets.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending as investors rally around the company's progress toward a Q4 BLA submission for its prostate cancer therapy, bolstered by strong institutional accumulation and anticipation of upcoming data at the ASTRO meeting. The community is actively discussing the stock's potential for a significant M&A event or strategic partnership, driven by its multi-asset platform and robust cash position extending into 2028.

Cipher Digital, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Digital Inc.

Cipher Digital is facing significant selling pressure and heightened volatility as traders weigh concerns over Texas regulatory developments and power grid compliance against the company's long-term infrastructure pipeline. While some community members are frustrated by the rapid price fluctuations and technical breakdowns, others are actively treating these lower levels as a strategic buying opportunity, betting on future data center capacity and hyperscaler demand.

Target Corp. engages in the operation and ownership of general merchandise stores. It offers food and general merchandise, clothing and household goods, electronics, and toys. Its brands include A New Day, All in Motion, Art Class, Auden, AVA & VIV, Boots and Barkley, Brightroom, Bullseye's Playground, Casaluna, Cat & Jack, Cloud Island, Colsie, dealworthy, Embark, Everspring, Favorite Day, Figmint, Future Collective, Gigglescape, Good & Gather, Goodfellow & Co, Hearth & Hand with Magnolia, Heyday, Hyde & EEK! Boutique, JoyLab, Kindfull, Kona Sol, Made By Design, Market Pantry, Mondo Llama, More Than Magic, Opalhouse, Open Story, Original Use, Pillowfort, Project 62, Room Essentials, Shade & Shore, Smartly, Smith & Hawken, Sonia Kashuk, Spritz, Sun Squad, Threshold, Universal Thread, up&up, Wild Fable, Wondershop, Xhilaration, California Roots, Casa Cantina, The Collection, Headliner, Jingle & Mingle, Rosé Bae, Photograph, SunPop, and Wine Cube. The company was founded by George Draper Dayton in 1902 and is headquartered in Minneapolis, MN.

Target Corp

Target is experiencing significant market volatility as investors weigh a strong earnings beat and raised guidance against concerns over broader consumer spending and potential tariff impacts. Community discussion is sharply divided between those viewing the pullback as a buying opportunity in a retail turnaround and traders focused on technical resistance levels after a rapid year-to-date rally.

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Tempus AI Inc. - Ordinary Shares - Class A

Tempus AI Inc

Tempus AI is experiencing significant upward momentum as investors highlight its expanding role in precision oncology and AI-driven healthcare, alongside optimism about potential short squeeze dynamics. The community is actively discussing the stock's strong technical performance, the potential impact of its strategic integration with Personalis, and the broader institutional interest in its data-heavy AI platform.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. It will generate domestically produced bitcoin powered by nuclear, hydro, and solar energy. It operates through the Digital Asset Mining and HPC Leasing segments. The company was founded by Paul B. Prager and Nazar M. Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is currently trending due to intense volatility and investor frustration as the stock consistently lags behind sector peers despite high-profile infrastructure contracts. The community is actively debating the impact of institutional ownership, persistent short-selling pressure, and the absence of insider buying, with sentiment split between long-term confidence in data center expansion and short-term disillusionment with the stock's poor relative price performance.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is experiencing significant volatility driven by reports of a critical VMware security vulnerability and analyst concerns regarding off-balance-sheet financing vehicles linked to AI infrastructure. While traders are actively debating whether the selloff is an unjustified reaction to market FUD or a necessary correction, many in the community view the weakness as a prime entry point for long-term positions leading into upcoming earnings.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

Merck is trending as a central player in a major biotech rally fueled by positive Phase 3 trial data for an mRNA-based individualized cancer vaccine developed in collaboration with Moderna. Investors are closely tracking these clinical results as a significant validation for the future of personalized oncology, while active community discussions center on Merck's broader strategy to expand its cancer pipeline and the potential ripple effects for smaller biotech partners in the space.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

New Strong Sell Stocks for August 14th

AMPH, CHT and HE have been added to the Zacks Rank #5 (Strong Sell) List on August 14, 2026.

Compared to Estimates, Amphastar (AMPH) Q2 Earnings: A Look at Key Metrics

Although the revenue and EPS for Amphastar (AMPH) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Amphastar Pharmaceuticals (AMPH) Q2 Earnings and Revenues Top Estimates

Amphastar (AMPH) delivered earnings and revenue surprises of +37.88% and +1.08%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2026

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2026 Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2026 PR Newswire RANCHO CUCAMONGA, Calif., Aug. 6, 2026 Net revenues of $183.9 million for the three months ended June...

Analysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out for

Amphastar (AMPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 6, 2026

Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 6, 2026 Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 6, 2026 PR Newswire RANCHO CUCAMONGA, Calif., July 29, 2026 RANCHO CUCAMONGA, Calif., July 29, 2026...

BridgeBio Pharma (BBIO) Moves 15.1% Higher: Will This Strength Last?

BridgeBio Pharma (BBIO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Is CRMD Stock a Buy Now After Strong Growth and New Risks?

CorMedix posted surging DefenCath-led revenue and stronger profitability, but reimbursement changes and execution risks could shape the stock's next phase.

CRMD Stock Outlook as DefenCath and Rezzayo Expand Growth Path

CorMedix is shifting from a single-product launch story as DefenCath drives revenue and Rezzayo adds long-term potential despite reimbursement headwinds.

New Strong Sell Stocks for June 23rd

ARR, AMTB and AMPH have been added to the Zacks Rank #5 (Strong Sell) List on June 23rd, 2026.

Amphastar Pharmaceuticals, Inc. engages in developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products, and insulin active pharmaceutical ingredients. It operates through Pharmaceutical Products segment. The company was founded by Zi-Ping Luo and Yong Feng Zhang on February 29, 1996 and is headquartered in Rancho Cucamonga, CA.

Amphastar Pharmaceuticals Inc

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '26	$0.86	--	--	N/A
Q2 '26	$0.62	$0.91	46.75%	BEAT
Q1 '26	$0.71	$0.42	-40.44%	MISSED
Q4 '25	$0.92	$0.73	-20.89%	MISSED
Q3 '25	$0.83	$0.93	12.68%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q2 '26

Historical Earnings